Search results
-
Revolution pushes home its pan-KRAS advantage
… Medicines Multi-KRAS inhibitor Ph1 data at ESMO 2023 Ph3 could begin in 2024 in NSCLC & pancreatic …
- 02/28/2024 - 15:37 -
BioNTech bails out Autolus
… capacity Data with automated production at ESMO 2023 ; pivotal trial in germ cell tumours due to start …
- 02/08/2024 - 15:05 -
Jazz joins the KRAS band with Redx deal
… which produced promising data – with caveats – at ESMO 2023. Quanta is taking an interesting approach, with … KRAS G12D siRNA Ph2 in pancreatic cancer; ESMO 2023: no difference in OS vs chemo MRTX1133 … KRAS G12D inhibitor Lacklustre ph1 data at ESMO 2023 (1/18 PRs) ASP3082 Astellas KRAS G12D …
- 02/08/2024 - 13:03 -
A cancer pipeline cull from AbbVie
… payload) Ph1 in solid tumours Data at ESMO 2023 in NSCLC: ORR 14% in 3L & 10% in 2L … SHP2 inhibitor Ph1/2 in solid tumours Data at ESMO 2023 + glecirasib (KRAS G12C) in NSCLC: ORR 51% …
- 02/06/2024 - 13:49 -
Pfizer shuffles its deck post-Seagen
… Beijing Immunochina Early China ph1 ; data at ESMO 2023: ORR 11% in 9 pts GCC19CART Car-T …
- 02/01/2024 - 14:51 -
Roche walks away from Hookipa’s KRAS immunotherapy
… immunotherapy HPV16+ HNSCC Ph1/2 1L + Keytruda ESMO 2023: 42% ORR (8/19 pts); more data due H1 2024; …
- 01/30/2024 - 13:42 -
Trodelvy throws second-line lung cancer another curveball
… and a secondary endpoint in Evoke-01. Source: ESMO 2023 & Gilead press release. Trial …
- 01/23/2024 - 15:04 -
ASCO-GI – Jacobio’s KRAS looks competitive in pancreatic
… cancer with its multi-RAS inhibitor RMC-6236 at ESMO 2023; however, this study excluded G12C mutants. …
- 01/18/2024 - 14:56 -
ASCO-GU preview: showdown for Exelixis
… in neuroendocrine prostate cancer 121 Had data at ESMO 2023; company sold to Merck & Co Keynote-564 …
- 01/25/2024 - 10:22 -
Cell cycle niche seeks clinical validation
… +/- platinum chemo, started Aug 2023; preclinical data at ESMO 2023 AZD8421 AstraZeneca Cycad-1 trial …
- 01/12/2024 - 17:23
